Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2018-08-13 Regulatory Filings
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Redhill Biopharma Ltd., with the SEC. It includes exhibits such as an underwriting agreement and legal opinions, but does not contain financial statements or detailed financial data. The document length is 2741 characters, which is relatively short and consistent with a regulatory filing or announcement rather than a full report. The text explicitly states it is a Form 6-K, which is used for current reports by foreign private issuers to disclose material information. There is no indication that this is an annual report, earnings release, or other detailed financial report. Therefore, this document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings like Form 6-K that do not fit other specific categories.
2018-08-13 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It contains a press release about a patent allowance and references incorporation by reference into registration statements. The document is short (1982 characters) and primarily serves as a regulatory announcement rather than a full report. It does not contain financial statements or detailed financial analysis. According to the rules, Form 6-K filings are typically regulatory filings for foreign issuers to report material information between annual reports. Therefore, this document fits best under Regulatory Filings (RNS).
2018-08-13 English
FORM 424B5
Capital/Financing Update Classification · 100% confidence The document is a Form 424B5 prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act, which is used for securities offerings. It details the offering of American Depositary Shares (ADSs) by RedHill Biopharma Ltd., including pricing, underwriting, risk factors, use of proceeds, and other offering-related information. The document is a registration statement supplement related to a capital raising event, not a financial report, earnings release, or management discussion. It is not an announcement of a report but the actual offering document. Therefore, it fits the category of Capital/Financing Update filings, which cover updates on company fundraising and financing activities.
2018-08-10 English
FORM 6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about the pricing of a $25 million underwritten offering. The document is short (2180 characters) and primarily serves as an announcement of a financing event. It references the press release as an exhibit and does not contain detailed financial statements or comprehensive financial data. According to the rules, such a document is best classified as a Capital/Financing Update (CAP) because it relates to company fundraising activities and capital structure changes.
2018-08-09 English
FORM 424B5
Capital/Financing Update Classification · 95% confidence The document is a preliminary prospectus supplement filed pursuant to Rule 424(b)(5) with the SEC, related to a securities offering by RedHill Biopharma Ltd. It includes detailed information about the offering of American Depositary Shares (ADSs), pricing, underwriting, risk factors, use of proceeds, and other offering-related disclosures. The document is a registration and offering prospectus supplement, which is a type of capital raising document. It is not an annual or quarterly report, earnings release, management discussion, or any other type of financial or governance report. It is clearly related to a financing activity and capital raising. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief notice, so it is not RPA or RNS. Confidence is high given the clear identification of the document as a prospectus supplement for a securities offering.
2018-08-09 English
AUGUST 6, 2018
Major Shareholding Notification
2018-08-06 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.